Medicine and Dentistry
Cohort Analysis
100%
Diffuse Large B-Cell Lymphoma
81%
Non-Hodgkin Lymphoma
80%
Hodgkin's Lymphoma
71%
Drug Megadose
63%
Psychoactive Drug
60%
Overall Survival
59%
Hazard Ratio
48%
Acute Myeloid Leukemia
47%
B-Cell Lymphoma
47%
Drug Use
47%
Methotrexate
47%
Myeloproliferative Neoplasm
47%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
38%
Follicular Lymphoma
35%
Cancer
29%
Mental Health
28%
Assisted Reproductive Technology
27%
Patient with Non-Hodgkins Lymphoma
25%
Diseases
25%
Population
24%
Burkitt's Lymphoma
23%
Systematic Review
23%
Health Care
23%
Osteoporosis
23%
Diabetes
23%
Clinical Trial
23%
Somatics
23%
Loss of Function Mutation
23%
Diabetes Mellitus
23%
Eosinophilic Esophagitis
23%
Central Nervous System
23%
Reproductive Medicine
23%
Classical Hodgkin Lymphoma
23%
Silo-Filler's Disease
23%
Glycon
23%
Case-Control Study
23%
Survivorship in Cancer Care
20%
Progression Free Survival
20%
Event Free Survival
17%
Bleomycin
16%
Proportional Hazards Model
15%
Prednisolone
14%
Malignant Neoplasm
13%
Childbirth
13%
Hematopoiesis
11%
Survival Analysis
11%
Blood Cell
11%
Acute Leukemia
11%
Erythrocyte
11%
Keyphrases
National Cohort Study
73%
Lymphoma Patients
65%
Denmark
47%
Reproduction Pattern
47%
Background Population
47%
High Risk
40%
Danish Population
30%
Lymphoma
29%
Population-based Study
28%
Adult Patients
28%
Eosinophilic Esophagitis
23%
Osteoporosis
23%
Sweden
23%
Population-based
23%
Acute Myeloid Leukemia
23%
Norway
23%
High-dose Methotrexate (HD-MTX)
23%
Aggressive Course
23%
Splenic Diffuse Red Pulp Lymphoma
23%
CNS Prophylaxis
23%
Psychotropic Drug Use
23%
Overall Survival
23%
Hodgkin Lymphoma Survivors
23%
Aggressive B-cell Lymphoma
23%
Childbirth
23%
Hodgkin Lymphoma
23%
Temporal Change
23%
Matched Cohort Study
23%
Cumulative Risk
23%
Pulmonary Disease
23%
Classical Hodgkin Lymphoma
23%
Metformin Use
23%
Hazard Ratio
19%
EFS24
19%
Risk Factors
16%
Central Nervous System Relapse
15%
Bleomycin
14%
Confidence Interval
13%
Diffuse Large B-cell Lymphoma (DLBCL)
11%
Bone Health
11%
Danish National Patient Registry
11%
Non-Hodgkin Lymphoma
11%
Female Sex
11%
Female Age
11%
Lymphoma Survivors
11%
Aggressive non-Hodgkin Lymphoma
11%
Reproductive Patterns
11%
Follicular Lymphoma
11%
High Dose
11%
Indolent Lymphoma
11%
Pharmacology, Toxicology and Pharmaceutical Science
Psychotropic Agent
84%
Cohort Study
73%
Acute Myeloid Leukemia
71%
Nonhodgkin Lymphoma
47%
Follicular Lymphoma
47%
Case-Control Study
47%
Myeloproliferative Neoplasm
47%
Overall Survival
44%
Diffuse Large B Cell Lymphoma
41%
Remission
26%
Patient Registry
23%
Clinical Trial
23%
Myelodysplastic Syndrome
23%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
23%
Eosinophilic Esophagitis
23%
B Cell Lymphoma
23%
Methotrexate
23%
Hodgkin Disease
23%
Prednisolone
23%
Classical Hodgkin Lymphoma
23%
Metformin
23%
Malignant Neoplasm
23%
Progression Free Survival
17%
Statin (Protein)
14%
Disease
11%
Antidepressant
9%
Typical Antipsychotic
9%
Distress Syndrome
7%
Automutilation
6%
Comorbidity
6%
Event Free Survival
5%
Disease Surveillance
5%
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
5%
Anxiolytic
5%
Symptom
5%
Population Study
5%
